HSIC
Henry ScheinNASDAQHealth CareMedical DistributionSnapshot 2026-05-08
As of May 8, 2026, HSIC has a composite score of 25.1 and a signal label of "mild favorable." The score reflects a medium confidence level of 76.7, with strengths in quality (69.2) and valuation (73.5), which is labeled as inexpensive. The score is provisional and influenced by various macroeconomic factors, including labor, rates, growth, and inflation.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.01
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.20 → $1.23 (+2.7% / 30d). 0 raised, 2 cut, 15 covering analysts.
0 upgrades, 0 downgrades / 30d, 3 maintained. 50% of analysts rate Buy.
4 PT revisions / 30d. Avg target 9.2% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
3 material events in the last 24 months — top 3 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Achieve 3% to 5% sales growth in 2026growthmixed65% progress
5/5: “2026 total sales growth is unchanged and expected to be approximately 3% to 5% over 2025.”
Why this status
Stated in 3 of last 3 quarters. Revenue grew from $3.17B in 2024-Q3 to $3.44B in 2025-Q4, indicating progress towards the 3% to 5% growth target for 2026. The trajectory shows consistent growth, aligning with management's guidance.
- 2.Maintain mid-single digit EBITDA growthgrowthmixed65% progress
5/5: “2026 Adjusted EBITDA is unchanged and expected to grow mid-single digits compared with 2025.”
Why this status
Stated in 3 of last 3 quarters. While specific EBITDA figures are not provided, the consistent guidance for mid-single digit growth suggests a stable trajectory. However, without precise numbers, the delivery on this priority remains less quantifiable.
- 3.Reaffirm EPS guidance for 2026growthmixed65% progress
5/5: “2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37.”
Why this status
Stated in 2 of last 2 quarters. The reaffirmation of EPS guidance for 2026 at $5.23 to $5.37 suggests confidence in achieving these earnings levels. However, without current EPS figures, the actual trajectory towards this target is unclear.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 25%; 252d 27%.
Drawdown — Max 1y −17%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.71 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 55/100, drawdown 66/100, beta 71/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 1 guided quarters · 442.1% avg surprise
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Achieve 3% to 5% sales growth in 2026
GrowthNew since 2026-05-05Henry Schein aims for total sales growth of approximately 3% to 5% over 2025.
MixedStated in 3 of last 3 quarters. Revenue grew from $3.17B in 2024-Q3 to $3.44B in 2025-Q4, indicating progress towards the 3% to 5% growth target for 2026. The trajectory shows consistent growth, aligning with management's guidance.
65%CEO/CFO:“2026 total sales growth is unchanged and expected to be approximately 3% to 5% over 2025.”Multiple sourcesSource dated 2026-05-05Stated 3 of last 8 quartersFirst seen 2026-05-05Show history (3)
- 2026-Q1Multiple sources
“2026 total sales growth is unchanged and expected to be approximately 3% to 5% over 2025.”
- 2025-Q4Multiple sources
“2026 total sales growth is expected to be approximately 3% to 5% over 2025.”
- 2025-Q3Multiple sources
“2025 total sales growth is raised to be approximately 3% to 4% over 2024.”
- #2
Maintain mid-single digit EBITDA growth
GrowthNew since 2026-05-05Henry Schein aims to achieve mid-single digit growth in adjusted EBITDA for 2026.
MixedStated in 3 of last 3 quarters. While specific EBITDA figures are not provided, the consistent guidance for mid-single digit growth suggests a stable trajectory. However, without precise numbers, the delivery on this priority remains less quantifiable.
65%CEO/CFO:“2026 Adjusted EBITDA is unchanged and expected to grow mid-single digits compared with 2025.”Multiple sourcesSource dated 2026-05-05Stated 3 of last 8 quartersFirst seen 2026-05-05Show history (3)
- 2026-Q1Multiple sources
“2026 Adjusted EBITDA is unchanged and expected to grow mid-single digits compared with 2025.”
- 2025-Q3Multiple sources
“2025 Adjusted EBITDA growth is unchanged and is expected to increase mid-single digits compared with 2024.”
- 2025-Q2Multiple sources
“2025 Adjusted EBITDA growth is unchanged and is expected to increase mid-single digits compared with 2024.”
- #3
Reaffirm EPS guidance for 2026
GrowthNew since 2026-05-05Henry Schein reaffirms its non-GAAP diluted EPS guidance for 2026 to be in the range of $5.23 to $5.37.
MixedStated in 2 of last 2 quarters. The reaffirmation of EPS guidance for 2026 at $5.23 to $5.37 suggests confidence in achieving these earnings levels. However, without current EPS figures, the actual trajectory towards this target is unclear.
65%CEO/CFO:“2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37.”Multiple sourcesSource dated 2026-05-05Stated 2 of last 8 quartersFirst seen 2026-05-05Show history (2)
- 2026-Q1Multiple sources
“2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37.”
- 2025-Q4Multiple sources
“2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
HSIC Henry Schein | +25 | inexpensive | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-05-05)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-05-05)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-053d agoItem 2.02
Results of Operations and Financial Condition. On May 5, 2026, Henry Schein, Inc. issued a press release reporting the financial results for the three months ended March 28, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this
earnings preannouncementneutralscore 61 - 2026-02-242mo agoItem 2.02
Results of Operations and Financial Condition. On February 24, 2026, Henry Schein, Inc. issued a press release reporting the financial results for the three months and full year ended December 27, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this
earnings preannouncementneutralscore 12 - 2025-12-095mo agoItem 1.01
Entry into a Material Definitive Agreement. On December 7, 2025, pursuant to Section 5.10(f) of the Strategic Partnership Agreement, dated January 29, 2025 (as amended, the “Agreement”), between Henry Schein, Inc. (the “Company”) and KKR Hawaii Aggregator L.P. (the “Investor”), the Investor, in its capacity as Investor Representative under the Agreement, notified the Company of its election to exercise the Extension Election. Accordingly, under the terms of the Agreement the Company’s Board o…
mna activitypositivescore 2 - 2025-09-098mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) As previously disclosed on April 1, 2025, James Breslawski transitioned from the role of President of Henry Schein, Inc. (the “Company”) to Senior Advisor and member of the Company’s Executive Management Committee (“current role”). On September 5, 2025, Mr. Breslawski transitioned out of his current role. In connection with his transition, Mr.…
executive changeneutralscore 0
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.